In today’s recent session, 2,624,690 shares of the Protalix BioTherapeutics, Inc.(NYSE:PLX) have been traded, and its beta is 0. Most recently the company’s share price was $5.14, and it changed around -$0.03 or -0.01% from the last close, which brings the market valuation of the company to $228.73 Million. PLX at last check was trading at a discount to its 52-week high of $7.02, offering almost -36.58% off that amount. The share price’s 52-week low was $2.04, which indicates that the recent value has risen by an impressive 60.31% since then. We note from Protalix BioTherapeutics, Inc.’s average daily trading volume that its 10-day average is 1.92 Million shares, with the 3-month average coming to 549.3 Million.
Protalix BioTherapeutics, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 1 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended PLX as a Hold, whereas 1 deemed it a Buy, and no one rated it as Underweight. Protalix BioTherapeutics, Inc. is expected to report earnings per share of -$0.08 for the current quarter.
Protalix BioTherapeutics, Inc. (NYSE:PLX): Trading Information Today
Although PLX has been showing red trend so far today with a performance of -0.68% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $5.48- on Monday, Feb 22 increased the stock’s daily price by 6.5%. The company’s shares are currently up 0.41% year-to-date, but still up 0.0787 over the last five days. On the other hand, Protalix BioTherapeutics, Inc. (NYSE:PLX) is 0.12% up in the 30-day period. We can see from the shorts that 505.55 Million shares have been sold at a short interest cover period of 0.92 day(s).
The consensus price target as assigned by Wall Street analysts is $11, which translates to bears needing to increase their stock price by 114.01% from its current value. Analyst projections state that PLX is forecast to be at a low of $11 and a high of $11. In order for the stock price to hit the forecast high, the stock would need to surge +114.01% from its current level, while the stock would need to crash 114.01% from its current level to reach the projected low.
Protalix BioTherapeutics, Inc. (PLX) projections and forecasts
Protalix BioTherapeutics, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +34.99 percent over the past six months and at a 72.36% annual growth rate that is well above the industry average of 14.1%. However, despite this, analysts have decided to cut back on their fiscal year 2021 revenue estimates. The rating firms predict that it will lose -500% in revenue this quarter, and will report a decline of -120% in the next quarter. The year-over-year growth rate is expected to be 1.1%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $11.99 Million in revenue for the current quarter. 1 analysts expect Protalix BioTherapeutics, Inc. to make $16.1 Million in revenue for the quarter ending March 01, 2021. The company’s sales for the same quarter a year ago was $17.76 Million. Analysts predict that the company’s current quarter sales will drop, forecast at -32.5%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%. Protalix BioTherapeutics, Inc. earnings are expected to increase by 68.3% in 2021, but the outlook is positive 25% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Protalix BioTherapeutics, Inc. (NYSE:PLX)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 32.84% of Protalix BioTherapeutics, Inc. shares, and 15.89% of them are in the hands of institutional investors. The stock currently has a share float of 23.67%. Protalix BioTherapeutics, Inc. stock is held by 30 institutions, with Burrage Capital Management LLC being the largest institutional investor. By Dec 30, 2020, it held 6.74% of the shares, which is about 2.47 Million shares worth $8.97 Million.
Renaissance Technologies, LLC, with 1.33% or 488.63 Thousand shares worth $1.77 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Bridgeway Funds Inc-Ultra Small Company Market Fund and Bridgeway Funds Inc-Ultra Small Company Fund were the top two Mutual Funds as of Dec 30, 2020. The former held 133100 shares worth $483.15 Thousand, making up 0.36% of all outstanding shares. On the other hand, Bridgeway Funds Inc-Ultra Small Company Fund held roughly 67Thousand shares worth around $243.21 Thousand, which represents about 0.18% of the total shares outstanding.